Dan Hudspeth has been named Chief Financial Officer of SynCardia Systems, Inc., the company announced on JUly 24, 2015.
“Mr. Hudspeth has over 20 years of international expertise in driving shareholder value,” says Michael Garippa, CEO and President of SynCardia Systems, Inc. “His experience includes U.S. and international business, finance and market development. We are very happy to have him as part of the company’s senior management team.”
SynCardia Systems, Inc. manufactures the SynCardia temporary Total Artificial Heart, the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart for patients dying of end-stage biventricular (both sides) heart failure. The company also manufactures the Freedom® portable driver, which powers the SynCardia Heart and provides significant mobility for clinically stable patients so they can be discharged from the hospital.
“I am excited to be a part of SynCardia Systems and its life-saving SynCardia Total Artificial Heart,” says Hudspeth. “I look forward to contributing to the company’s growth.”
Hudspeth has an extensive background in financing, accounting, manufacturing and distribution within high-growth private equity-based and public companies.
His leadership in three public offerings and more than 30 private equity and debt financing has led to more than $600 million of capital formation. He was instrumental in five merger and acquisition transactions and exits that represented over $400 million in shareholder value.
A certified public accountant inactive, Hudspeth most recently provided interim executive and board advisory services to venture capital and private equity-backed companies through his company, Cohesive Strategy LLC. He has served as the chief financial officer of Genomica Corp., Rally Development Corp. and Allos Therapeutics.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world’s first and only FDA, Health Canada and CE approved Total Artificial Heart for use as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,400 implants of the SynCardia Total Artificial Heart account for over 400 patient years of life on the device. Since January 2010 more than 550 SynCardia Hearts have been implanted.
The youngest patient to receive a SynCardia Heart was 9 years old; the oldest was 80 years old. The longest a patient has lived with a SynCardia Heart was nearly four years (1,374 days) before receiving a successful donor heart transplant Sept. 11, 2011.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to be discharged from the hospital to live at home and in their communities. The wearable Freedom driver has been used by more than 200 patients, accounting for over 130 years of support.